This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Brivaracetam
UCB Pharma's structurally optimized successor to levetiracetam — same SV2A target, 15-30× higher binding affinity, same partial-onset…
Aliases (6)
Overview
What is Brivaracetam?
Brivaracetam (brand name Briviact) is a third-generation racetam-class antiepileptic, FDA-approved as adjunctive and monotherapy for partial-onset seizures. It is a structural analog of levetiracetam with higher affinity for the SV2A target.
Key Benefits
Effective as adjunct or monotherapy for partial-onset seizures, faster brain penetration than levetiracetam, lower rate of behavioral side effects (irritability, mood changes) than levetiracetam.
Mechanism of Action
Selective high-affinity ligand for synaptic vesicle protein 2A (SV2A) — modulates neurotransmitter release at nerve terminals. ~20x higher SV2A affinity than levetiracetam, with no significant action at classical neurotransmitter receptors.
Pharmacokinetics
▸Brand options4 known
Status"Rx (FDA-approved Feb 2016 for adjunctive treatment of partial-onset / focal seizures in patients ≥4 years; expanded to monotherapy 2017 in US, ≥1 month old in 2021). Schedule V (US — DEA scheduled at launch due to behavioral-AE profile in trials, though abuse signal is essentially absent in post-marketing data; same scheduling decision as pregabalin and lacosamide). UK / EU: POM (prescription-only, no controlled scheduling)."
Research Indications
SV2A — what it is and why it matters
Synaptic vesicle glycoprotein 2A (SV2A) is one of three SV2 isoforms (A, B, C) — 12-transmembrane integral membrane proteins embedded in …
Brivaracetam's affinity advantage
Binding affinity at SV2A: - Brivaracetam: Kd ~50-80 nM (depending on assay) - Levetiracetam: Kd ~1-6 µM - Ratio: ~15-30× higher affinity …
The "cleaner pharmacology" design intent
UCB's explicit design brief for brivaracetam (UCB-34714) was to retain SV2A activity while removing off-target activity that was hypothes…
Pharmacokinetics
- Absorption: rapid and complete oral bioavailability (~100%); food slows absorption but does not reduce AUC. - T-max: 1 hour (oral). - P…
Why "third-generation" terminology
- First-generation AEDs: phenobarbital, phenytoin, carbamazepine, valproate, ethosuximide. 1910s-1970s. High AE burden, narrow therapeuti…
Peptide Interactions
redundant (same target, lower-affinity parent compound). FDA label specifically discourages co-administration; one consistent finding is that adding brivarac…
reduce brivaracetam exposure by 25-50%; dose adjustment upward needed.
additive sedation in some users — not a contraindication but a common AE compounder.
the directional mismatch (brivaracetam is mildly sedating in many users; modafinil is wake-promoting) makes co-administration mechanistically incoherent for …
no PK or PD interactions of concern.
minimal interaction. Brivaracetam's clean drug-interaction profile is a clinical selling point.
specifically: brivaracetam's amidase metabolite (BRV-AC) is increased by carbamazepine, but the metabolite is inactive — clinically not significant.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety 13
Side Effects
- 1Somnolence (~14%)
- 2Dizziness (~12%)
- 3Fatigue (~9-13%)
- 4Headache (modest excess over placebo)
- 5Irritability (~3-5% — lower than levetiracetam's ~7-13% rate, but still present)
- 6Nausea / vomiting
- 7Decreased appetite
- 8Insomnia or sleep disturbance
- 9Nasopharyngitis / upper respiratory infection (modest excess in trials)
- 10Constipation
- 11Ataxia / coordination disturbance (mild; less than topiramate/lamotrigine)
- 12Diplopia / blurred vision
- 13Mood changes (depression, anxiety) — present but reduced vs. levetiracetam
When to Stop
- Suicidal ideation / behavior — FDA class warning for all AEDs (2008, based on pooled meta-analysis showing ~2× increased suicidal-ideation incidence vs. placebo across the AED class). Brivaracetam shares this label warning. Screen at initiation; monitor first 8-24 weeks especially.
- Hypersensitivity reactions / DRESS / SJS: Rare but reported. Typical AED watch period 8-12 weeks.
- Bronchospasm / angioedema: Very rare; reported in post-marketing surveillance.
- Hepatic enzyme elevation: Modest AST/ALT elevations have been reported; clinically significant hepatotoxicity is rare.
- Bone marrow suppression / leukopenia: Rare; mild reductions in WBC/lymphocyte counts reported in some patients. CBC monitoring not routinely required but reasonable in long-term users.
- Behavioral / psychotic reactions: Aggression, anger, agitation, psychotic symptoms reported but at lower rates than levetiracetam — the design hypothesis held in clinical use, with the gap roughly halved in head-to-head and conversion data.
- First 4-8 weeks: somnolence, dizziness, behavioral AE peak. Most AEs that emerge later are typically not new-onset.
- First 8-12 weeks: hypersensitivity / DRESS window.
- Suicidal ideation screen: at baseline and during first 24 weeks of any AED initiation per FDA class guidance.
- Discontinuation: taper recommended over 1-2 weeks (rather than abrupt) to reduce withdrawal-seizure risk in the epilepsy population. In a hypothetical non-epilepsy user, abrupt discontinuation has not been formally studied but is presumably lower-risk than in seizure-prone individuals.
References
Brivaracetam — Wikipedia
high-level pharmacology, regulatory status, FDA approval timeline.
View StudyBrivaracetam: A Novel Antiepileptic Drug for Focal-Onset Seizures — Annals of Pharmacotherapy 2017
clinical pharmacology and Phase III synthesis.
View StudyThe Synaptic Vesicle Glycoprotein 2A Ligand Levetiracetam Inhibits Presynaptic Ca²⁺ Channels Through an Intracellular Pathway — Lynch et al. 2004 PNAS
SV2A target identification for the racetam-family AEDs.
View StudyDiscovery of brivaracetam, a high-affinity selective SV2A ligand — Kenda et al. 2004 J Med Chem
original UCB design / discovery paper.
View StudyBrivaracetam: Rationale for Discovery and Preclinical Profile of a Selective SV2A Ligand for Epilepsy Treatment — Matagne et al. 2008 Br J Pharmacol
preclinical pharmacology and selectivity rationale.
View StudyBrivaracetam as Adjunctive Treatment for Uncontrolled Partial Epilepsy in Adults — Klein et al. 2015 Neurology (N01253)
pivotal Phase III trial.
View StudyAdjunctive Brivaracetam for Uncontrolled Focal and Generalized Epilepsies — Ryvlin et al. 2014 Neurology (N01252)
pivotal Phase III trial.
View StudyBrivaracetam as Adjunctive Treatment for Uncontrolled Partial Epilepsy in Adults — Biton et al. 2014 Epilepsia (N01358)
pivotal Phase III trial.
View StudyLong-term safety and efficacy of brivaracetam — Toledo et al. 2016 Epilepsia
open-label extension.
View StudyConversion from levetiracetam to brivaracetam: real-world experience — Steinhoff et al. 2017
conversion AE-improvement evidence.
View StudyCognitive effects of antiepileptic drugs — Meador 2016 Epilepsy & Behavior
comparative cognitive AE synthesis across AEDs.
View StudyBriviact (brivaracetam) FDA Prescribing Information — UCB
FDA label, dosing, AE rates, drug interactions.
View StudyBrivaracetam: a novel antiepileptic drug — Klitgaard et al. 2016 Epilepsy Currents
UCB summary of mechanism, pharmacokinetics, clinical profile.
View StudySV2A as a Target for Synaptic Density Imaging — Finnema et al. 2016 Sci Transl Med
[¹¹C]UCB-J SV2A PET imaging in humans.
View StudyBrivaracetam in Status Epilepticus — Strzelczyk et al. 2017 Epilepsy Behav Case Rep
IV use case series.
View StudyFDA approves Briviact for focal seizures in patients 1 month and older — UCB 2021
pediatric label expansion.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.